Press Room

ISPE Annual Meeting

Start
Sunday, October 15, 2023
End
Wednesday, October 18, 2023
Location: Las Vegas, USA

ISPE Annual Meeting offers the opportunity to engage in industry-critical conversations. A comprehensive education program provides attendees with technical sessions on the latest developments in supply chain, operations, facilities, equipment, information systems, product development, production systems, quality systems, regulatory guidance and cutting-edge industry innovations.

On October 17 (11am) Anthony Tantuccio, Fellow Scientist at Hovione, is hosting a presentation on “Continuous Tableting Control Strategies: When and How to Apply Them” where he will share key considerations about appropriate control strategies in CT and how Hovione is positioning itself to enable them. This presentation is included on the topic “Advancements in Drug development and Equipment design”.

Session description:
A CDMO’s role is particularly critical for the adoption of CM in that an equipment standard needs to be established where most of the industry can seamlessly integrate with their own development, manufacturing, and supply chains.

The processes and knowledge of owning and operating the technology must be broad, yet robust, to assure that the benefits outweigh the perceived risks by a meaningful margin. Equally important and fundamental is the control strategy, which provides the final assurance that the chosen manufacturing process is fit for the intended product and will provide the desired quality. It is the fundamental component which is the most challenging to standardize because the drug pipelines are constantly evolving, and demand volumes are volatile these days.

This means it is not possible to have a one-size-fits-all control strategy, that depending on the product lifecycle and the nature of the formulation, the control strategy too may need to be flexible and evolve. This talk will focus on the key themes pertinent to the robust and pragmatic continuous tableting control strategies which Hovione is positioning itself to offer and deploy.

Contact our experts today to find out more aboutContinuous Tableting at Hovione.

Find out more about ISPE 
 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026